Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L N Newcomer

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The American Journal of Managed Care|August 29, 1998
Role of technology assessment in health benefits coverage for medical devicesN M Braslow, D Shatin, D B McCarthy, et al.
American Journal of Clinical Oncology|August 1, 1982
Splenectomy in Hodgkin's disease: no therapeutic benefitL N Newcomer, E C Cadman, L R Prosnitz, et al.
Effective Clinical Practice : ECP|January 11, 2001
First do no harm--to err is humanE B Larson, L N Newcomer, T A Brennan, et al.
Cancer Treatment Reports|June 1, 1985
Phase I study of divided-dose vinblastine in advanced malignancyJ A Young, D Westlake, G W Schnetzer, et al.
Cancer|August 1, 1982
The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapyL N Newcomer, M I Nerenberg, E C Cadman, et al.
Cancer|January 15, 1982
Bone involvement in Hodgkin's diseaseL N Newcomer, M B Silverstein, E C Cadman, et al.
Cancer Treatment Reports|June 1, 1982
Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphomaL N Newcomer, E C Cadman, M I Nerenberg, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The American Journal of Managed Care|August 29, 1998
Role of technology assessment in health benefits coverage for medical devicesN M Braslow, D Shatin, D B McCarthy, et al.
American Journal of Clinical Oncology|August 1, 1982
Splenectomy in Hodgkin's disease: no therapeutic benefitL N Newcomer, E C Cadman, L R Prosnitz, et al.
Effective Clinical Practice : ECP|January 11, 2001
First do no harm--to err is humanE B Larson, L N Newcomer, T A Brennan, et al.
Cancer Treatment Reports|June 1, 1985
Phase I study of divided-dose vinblastine in advanced malignancyJ A Young, D Westlake, G W Schnetzer, et al.
Cancer|August 1, 1982
The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapyL N Newcomer, M I Nerenberg, E C Cadman, et al.
Cancer|January 15, 1982
Bone involvement in Hodgkin's diseaseL N Newcomer, M B Silverstein, E C Cadman, et al.
Cancer Treatment Reports|June 1, 1982
Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphomaL N Newcomer, E C Cadman, M I Nerenberg, et al.
Pageof 3